The FDA approved Orzeyful (oveporexton) on Aug. 5 as the first medication aimed at treating the full range of narcolepsy type 1 symptoms in adults. Orzeyful directly targets the loss of orexin (hypocretin) signaling—the underlying biological cause of the disorder—and is taken as an oral tablet twice daily. The approval was granted to Takeda Pharmaceuticals America, and FDA officials said the drug addresses the condition’s biology rather than only individual symptoms.
FDA Approves Orzeyful — First Drug to Treat Full Range of Narcolepsy Type 1 Symptoms in Adults
The U.S. Food and Drug Administration headquarters is shown in Silver Spring, Md. File photo by Jim Lo Scalzo/EPA-EFE/
Aug. 5 — The U.S. Food and Drug Administration on Wednesday approved Orzeyful (oveporexton) as the first medication specifically intended to treat the full range of symptoms associated with narcolepsy type 1 in adults, the agency said in a release.
The FDA described narcolepsy type 1 as a rare, lifelong neuropsychiatric sleep disorder caused by the loss of brain cells that produce orexin (also called hypocretin), the chemical messenger that regulates wakefulness, sleep and muscle tone. Orzeyful is the first drug approved to directly target that loss of orexin signaling.
“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it,” said Tiffany Farchione, director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.”
What Symptoms It Targets
The disorder’s hallmark symptoms include excessive daytime sleepiness and cataplexy (sudden muscle weakness triggered by strong emotions). Other common features are sleep paralysis, disrupted nighttime sleep and hypnagogic or hypnopompic hallucinations that occur at the edge of falling asleep or waking.
How It’s Taken and How It Works
Orzeyful is an oral tablet to be taken twice daily. According to the FDA, the medication works by directly activating the same brain receptor that naturally produced orexin would stimulate, addressing the underlying biological cause rather than only treating individual symptoms.
The approval for Orzeyful was granted to Takeda Pharmaceuticals America. The FDA release framed the approval as a significant step because it targets the core mechanism of narcolepsy type 1.
Note: This article summarizes the FDA announcement. Consult prescribing information and professional guidance for detailed safety, efficacy and prescribing instructions.
Help us improve.
